Leerink Partnrs Issues Negative Forecast for ALNY Earnings

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Stock analysts at Leerink Partnrs decreased their Q1 2025 earnings estimates for shares of Alnylam Pharmaceuticals in a research report issued to clients and investors on Wednesday, April 2nd. Leerink Partnrs analyst M. Foroohar now anticipates that the biopharmaceutical company will earn ($0.74) per share for the quarter, down from their previous estimate of ($0.73). The consensus estimate for Alnylam Pharmaceuticals' current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Alnylam Pharmaceuticals' Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($1.86) EPS and FY2027 earnings at $1.76 EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03).

A number of other research analysts have also recently issued reports on the company. Sanford C. Bernstein cut their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a report on Tuesday, January 7th. Bank of America boosted their price target on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a research report on Friday, March 21st. Stifel Nicolaus raised their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a report on Monday, March 31st. HC Wainwright reissued a "buy" rating and issued a $500.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. Finally, Redburn Atlantic started coverage on Alnylam Pharmaceuticals in a report on Monday, March 31st. They set a "buy" rating and a $353.00 price target for the company. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $315.58.

Remove Ads

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock traded up $11.49 during midday trading on Monday, hitting $237.77. 1,577,336 shares of the company were exchanged, compared to its average volume of 863,403. The firm has a 50 day simple moving average of $253.20 and a 200-day simple moving average of $258.37. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The firm has a market cap of $30.93 billion, a P/E ratio of -109.57 and a beta of 0.30. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $304.39.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Capital World Investors raised its position in shares of Alnylam Pharmaceuticals by 0.6% during the fourth quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock worth $3,906,284,000 after purchasing an additional 92,101 shares during the period. Vanguard Group Inc. raised its holdings in Alnylam Pharmaceuticals by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company's stock worth $2,996,296,000 after buying an additional 98,303 shares during the period. Capital Research Global Investors raised its holdings in Alnylam Pharmaceuticals by 32.9% during the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock worth $1,639,767,000 after buying an additional 1,724,610 shares during the period. Regeneron Pharmaceuticals Inc. bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 39.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock valued at $1,031,705,000 after buying an additional 1,245,195 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CFO Jeffrey V. Poulton sold 967 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $246,749.39. Following the transaction, the chief financial officer now directly owns 32,786 shares of the company's stock, valued at $8,366,003.62. This trade represents a 2.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Pushkal Garg sold 52,592 shares of the business's stock in a transaction on Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares of the company's stock, valued at $3,416,865. This trade represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.